The Female Health Company (“FHC” or the “Company”) manufactures, markets and sells the FC2 female condom, the only currently available product under a woman’s control that is approved by the U.S. Food and Drug Administration (FDA), which provides dual protection against unintended pregnancy and sexually transmitted infections (“STIs”), including HIV/AIDS. In October 2009, the Company completed the transition from its first generation product, FC1, to its second generation product, FC2, and production of FC1 ceased. Although FC1 production has ceased, the Company retains ownership of certain world-wide rights to FC1, as well as various patents, regulatory approvals and other intellectual property related to FC1.The Female Health Company is publicly traded on the NASDAQ-CM stock exchange under the symbol "FHCO".
FC Female Condoms (FC) have undergone extensive testing for efficacy, safety and acceptability in the United States and many countries around the world. Certain studies have shown that having FC available allows women and men to access more prevention options and results in an increase in protected sex acts and a decrease in STIs, including HIV/AIDS. FC have high acceptability among both men and women in many countries.
The FC2 Female Condom® (FC2) is available in the United States and about 130 countries around the world. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in the U.S., the European Union, Canada, Australia, the Republic of South Africa. Japan, the People’s Republic of China, Spain, Mexico, Greece, Turkey and by the African Regional Intellectual Property Organization (ARIPO), which includes Botswana, The Gambia, Ghana, Kenya, Lesotho, Malawi, Mozambique, Namibia, Sierra Leone, Sudan, Swaziland, Uganda, Tanzania, Zambia and Zimbabwe. FC2 patent applications are pending in various other countries. The FC2 Female Condom® is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted infections (including HIV/AIDS), and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.